You are currently viewing a placeholder content from Vimeo. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.

More Information
Unblock content Accept required service and unblock content

Tiefenbacher Pharmaceuticals – a part of Tiefenbacher Group – at DCAT 2023: Thanks for meeting us in New York City!

DCAT week – one of the world´s most important pharma events – has just come to an end. It was four very successful and inspiring days for TIEFENBACHER in New York City. What a pleasure to present our latest product portfolio and innovations and to connect with existing and potential new partners. Check out our short video to get some impressions at DCAT 2023!

TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms (FDF) and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com